3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
27
Observational
1
Sponsor
Cancer Type
Lymphoid
9
Plasma cell
8
Tumor-Agnostic
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Conditions
Recurrence
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Interventions
Blood Specimen Collection
15
Imatinib Mesylate
10
Flow Cytometry
10
nilotinib
8
Surveys and Questionnaires
8
Polymerase Chain Reaction
8
ponatinib
6
Cytogenetic Analysis
6
ruxolitinib
5
bosutinib
5
Psychiatric Rehabilitation
5
Dasatinib
5
Therapeutics
4
Interviews as Topic
4
Biopsy
4
asciminib
3
Observation
3
Microarray Analysis
3
In Situ Hybridization, Fluorescence
3
Immunoenzyme Techniques
3
Amplified Fragment Length Polymorphism Analysis
3
olverembatinib
2
fludarabine
2
Watchful Waiting
2
Tyrosine Kinase Inhibitors
2
Molecular Diagnostic Techniques
2
Influenza Vaccines
2
Immunologic Techniques
2
Immunohistochemistry
2
Hydroxyurea
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Lenalidomide
×
Myeloid
×
Clear all
NCT04036448
2025-03-11
RevlimidPMS
Celgene
Completed
28 enrolled